Napo Pharmaceuticals Inc
21 April 2008


For immediate release                                 21 April 2008

                           Napo Pharmaceuticals Inc.

                                 Share Purchase


Notification of Transactions of Directors, Persons Discharging Managerial
Responsibility or Connected Persons


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR
FROM THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN


South San Francisco, California,   21 April, 2008 - South San Francisco,
California, Napo Pharmaceuticals, Inc., (LSE: NAPL), (the 'Company')-The Company
announces that on 21 April 2008, in relation to transactions of Directors and
Persons Discharging Managerial Responsibility, it was informed that on that day
Sir William Young, the Non-executive Director and Chairman, purchased 132,870
Common Shares at a price of 1.50 pence per share.


These shares were purchased on 18 April 2008. Following the purchase of these
Common Shares, Sir William Young held a total holding of 132,870 Common Shares
in the Company (including any held by a trust in which he has an interest)
amounting to 0.25 per cent of the issued share capital.


For more information please contract:


Napo Pharmaceuticals, Inc.

Lisa Conte, Chief Executive Officer

(001) + 650 616 1902


Charles Thompson, Chief Financial Officer

(001) + 650 616 1903


Buchanan Communications

(44) + 020 7466 5000

Tim Anderson, Mary-Jane Johnson


About Napo Pharmaceuticals, Inc.


Napo Pharmaceuticals, Inc. focuses on the development and commercialisation of
proprietary pharmaceuticals for the global marketplace in collaboration with
local partners. Napo was founded in November 2001, and is based in California,
USA with a subsidiary in Mumbai, India.



Napo's late-stage proprietary gastro-intestinal compound, crofelemer, is in
various stages of clinical development for four distinct product indications,
including a late-stage Phase 3 program:


   CRO-HIV for AIDS diarrhoea, Phase 3

   CRO-IBS for diarrhoea irritable bowel syndrome ('D-IBS'), Phase 2

   CRO-ID for acute infectious diarrhoea (including cholera), Phase 2

   CRO-PED for paediatric diarrhoea, Phase 1


The FDA has granted fast-track status to CRO-IBS and CRO-HIV.


Crofelemer, a proprietary patented agent, is extracted from Croton lechleri, a
medicinal plant which can be sustainably harvested from several countries in
South America. Napo also plans to develop an early clinical stage product,
NP-500, for the treatment of insulin resistant diseases of Type II diabetes and
metabolic syndrome (Syndrome X; pre-diabetic syndrome). Napo also has a plant
library of approximately 2,300 medicinal plants from tropical regions, and Napo
has entered two screening relationship associated with this collection.


Currently, products are based on the chemical and biological diversity derived
from plants with medicinal properties, but future products may be in-licensed
from other sources.


Napo has partnerships with Glenmark Pharmaceuticals Limited of India and
AsiaPharm Group Ltd. of China.


For more information please visit www.napopharma.com.



                      This information is provided by RNS
            The company news service from the London Stock Exchange